|Day Low/High||50.85 / 51.51|
|52 Wk Low/High||48.01 / 66.55|
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Regeneron Pharmaceuticals, Inc.
Cramer isn't selling AK Steel, Kellogg or Clorox.
Worried about a bad event? There will be money coming off the sidelines afterward. Be prepared to buy on weakness.
Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announces top-line results from the exploratory Phase 2 PRIDE-HD study.
FNV, BFS, TEVA, SCX and UNFI were all recently downgraded by TheStreet’s Quant Ratings.
Teva and Intel will develop a wearable device that monitors they symptoms of patients with Huntington disease.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the launch of an authorized generic of Cubicin ®1 (daptomycin for injection) 500 mg per vial in the United States.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announces a collaboration with Intel Corporation to develop a unique wearable device and machine learning platform for use in Huntington disease (HD).
Teva, the worlds largest generic drug manufacturer, is currently looking like one of the best buys in the market.
Here are Tuesday's top research calls, including a downgrade for Anthem, an upgrade for DR Horton and new coverage on Chevron and Under Armour.
Without it, the uncertainty would be incredible between now and November.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: PFMT, UTSI, VBFC Downgrades: AMCN, BGG, CSTE, GBLI, NEWS, NTRA, SHLM, SUNS, TEVA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
The drug company has several generic drugs that will compete with the likes of Pfizer's Viagra and Valeant's Acanya.
Teva Pharmaceuticals (TEVA) said it hopes to gain FDA approval by 2017 or 2018 for a generic EpiPen device.
The Consumer Union is alleging that Mylan may have paid Teva to withhold its EpiPen competitor from the market.
Here's a closer look at five dividend stocks that Paulson & Co. owned in the most recently reported quarter.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that data on COPAXONE ® (glatiramer acetate injection), a product for relapsing forms of multiple sclerosis (MS), and laquinimod, an...
Here are three recent examples of how the patient can profit.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Wells Fargo Healthcare Conference.
Teva stock rating was increased to 'outperform' with a $66 price target at Oppenheimer earlier today.
When it comes to investing in health care, hedge fund pro John Paulson knows his stuff.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that five company-sponsored abstracts will be presented at the 2016 European Respiratory Society (ERS) International Congress in London, England on...
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will host a conference call and live webcast along with a slide presentation on Friday, September 9, 2016 at 8:00 a.
While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.